Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

biotech

  • Home
  •  
  • biotech



  • Most Read
  • Latest Comments
  • Microba launches gut health test for clinicians, expanding their B2B business
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Microba launches gut health test for clinicians, expanding their B2B business
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Microba launches gut health test for clinicians, expanding their B2B business
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Microba launches gut health test for clinicians, expanding their B2B business
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Microba launches gut health test for clinicians, expanding their B2B business
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Microba launches gut health test for clinicians, expanding their B2B business
    • News

    Microba launches gut health test for clinicians, expanding their B2B business

    Eat Maccas for dinner three nights in a row and I guarantee you won’t feel too flash. Replace your deep fried goodies from the golden arches with a quinoa salad and your body will thank you.  The effects may be due to the link between our health and gut microbiome which is determined by what

    Read More
    Public
  • Arovella is helping insomnia sufferers get some shut eye
    • News

    Arovella is helping insomnia sufferers get some shut eye

    You know those nights. The ones where you toss and turn, where it’s too hot, or too cold. The ones where you count sheep, stare at the ceiling, and eventually abandon your attempt at sleep to go eat cheese out of the bag at midnight (just admit it, we all do it). Some have these

    Read More
    Public
  • Why Orthocell has blown my mind this morning
    • Opinion

    Why Orthocell has blown my mind this morning

    When I read Orthocell’s (ASX: OCC) company announcement I had to do a double take.  Why?  Because they are casually RESTORING FUNCTION TO PARALYSED LIMBS. Go back, read that again. Scoop your jaw off the floor.  That’s right, regenerative medicine company Orthocell (ASX: OCC) has received final data for their nerve reconstruction study were theyRead More
    Public
  • Alterity Therapeutics moves neuroprotective drug to Phase 2 trials
    • News

    Alterity Therapeutics moves neuroprotective drug to Phase 2 trials

    Seven to ten years. That’s how long someone diagnosed with multiple system atrophy (MSA) has to live from when symptoms first appear. The progressive disease results in the gradual functional decline of the body’s involuntary functions such as blood pressure, breathing, bladder function and motor control. Often confused with Parkinson’s which is characterised by the

    Read More
    Public
  • The Cancer Index: Why investing in oncology biotechs is more science than art
    • News

    The Cancer Index: Why investing in oncology biotechs is more science than art

    Despite what it may look like, investing in biotechs is more science than art. The sector holds intrinsically higher risk, but investing in it can be well worth it to those willing to take the plunge. In fact, over the last twenty years biotech firms have outperformed the S&P 500 and both the medtech andRead More
    Public
  • Cynata to tackle common transplant side effect with lead drug CYP-001
    • News

    Cynata to tackle common transplant side effect with lead drug CYP-001

    The first successful organ donation occurred in 1954 where a living donor gave a kidney to his identical twin. Since then, organ donation has become a routine practice with over 25,000 transplants conducted per year in US hospitals. Transplantation is far from simple, with an immense amount of preparation and aftercare required for recipients. A

    Read More
    Public
  • «
  • ‹
  • 4
  • 5
  • 6
  • 7
  • 8
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.